Publications

Peer reviewed publications:

MBNL1 alternative splicing isoforms play opposing roles in cancer.

PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-Tumorigenic Effects of Senescent Cells.

SRSF3 maintains transcriptome integrity in oocytes by regulation of alternative splicing and transposable elements.

Induced-Decay of Glycine Decarboxylase Transcripts as an Anticancer Therapeutic Strategy for Non-Small-Cell Lung Carcinoma.

RNAl Reveals Phase-Specific Global Regulators of Human Somatic Cell Reprogramming.

Wee, K.B.*, Lee, R.T.C.*, Lin, J., Pramono, Z.A.D., Maurer-Stroh, S.
Discovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous
Heterosubtypic Targeting that Hedge against Antiviral Resistance.


MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis.


Pao, P.W., Wee, K.B., Yee, W.C., Pramono, Z.A.D.
Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of *SMN2* gene.


A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in DMD gene.


Wee, K.B.*, Yio, W.K., Surana, U., Chiam, K.H.
Transcription factor oscillations induce differential gene expressions.


Wee, K.B., Surana, U., Aguda, B.D.
Oscillations of the p53-Akt network: implications on cell survival and death.


Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.


Wee, K.B., Aguda, B.D.
Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death.

Transition to quorum sensing in an Agrobacterium population: A stochastic model.

**Patents filed:**

Wee, K.B.
Method For Screening Splicing Variants Or Events.
**WO 2019/032054 A1.**

Guccione, E., Wee, K.B., Bertoletti, A.
Modifying T lymphocytes function with Antisense Oligonucleotides (ASOs) for personalized immune therapy.
**SG Patent Application No.: 10201705285S.**
*Exclusive licensed on 14 Sep 2018.*

Surana, U., Wee, K.B., Lin, J., Lim, B.
Steric hindrance antisense oligonucleotides (shAONs) targeting glycine decarboxylase (GLDC) expression as drug candidates for non-small cell lung carcinoma (NSCLC) and other cancers.
**SG Patent Application No.: 10201609048R.**

Guccione, E., Wee, K.B.
Method of Treating Cancer by Antisense Oligonucleotide Targeting PRDM15.
**WO 2018/044239.**

Pramono, Z.A., Yee, W.C., Lai, P.S., Wee, K.B.
Antisense oligonucleotides and uses thereof.
**WO 2011/078,797.**

**Trade-secrets lodged:**

Wee, K.B.
Methods for the rational design of highly efficacious steric hindrance antisense oligonucleotides (stAONs) for the specific modulations of RNA.
**IHPC/Z/09979 (2017).**
Wee, K.B., Pramono, Z.A., Lee, R.T.C., Surana, U., Yio, W.K., Maurer-Stroh, S.
IHPC/Z/07462 (2012).

Wee, K.B., Pramono, Z.A., Yee, W.C.
Methodology for the rational design of efficient AONs to induce specific exon skipping.
IHPC/Z/06180 (2010).

Wee, K.B., Pramono, Z.A., Lee, R.T.C.
Enabling platform for AON target identification and guided-design of efficient AON molecules for disease therapy and biological research.
IHPC/Z/06065 (2010).